Scirpa Riccardo, Follesa Federico, De Fazio Ludovica, Cittadini Edoardo, Francia Pietro, Tini Giacomo, Autore Camillo, Barbato Emanuele, Musumeci Beatrice
Cardiology, Clinical and Molecular Medicine Department, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome (Lazio) 00185, Italy.
IRCSS San Raffele Pisana, Via Della Pisana; Department of Clinical and Molecular Medicine, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome (Lazio) 00185, Italy.
Heart Fail Clin. 2024 Jul;20(3S):e33-e44. doi: 10.1016/j.hfc.2024.09.004. Epub 2024 Oct 18.
Cardiac amyloidosis is an infiltrative myocardial disease whose prevalence significantly increased in recent years. Its clinical history is changing due to the advent of novel therapies, and careful risk stratification has become impelling. Arrhythmias, frequently found during the course of the disease, include conduction system disease, atrial fibrillation (AF), and ventricular arrhythmias (VAs). Arrhythmic risk stratification is a key to identify those patients at higher risk to develop advanced atrioventricular blocks, asymptomatic AFs, or major VAs. This carries significant clinical implications concerning the indication and timing of implantable cardiac devices, as well as the initiation of anticoagulation therapy.
